« PrécédentContinuer »
mi iiiiiii ill mi mi Iiii ill ill ii|jpi mi mill mi mi mi
(12) United States Patent
Szeto et al.
(io) Patent No.: (45) Date of Patent:
US 7,704,954 B2 Apr. 27, 2010
(54) METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS
(75) Inventors: Hazel H. Szeto, New York, NY (US);
Kesheng Zhao, Jackson Heights, NY
(US); Hugh D. Robertson, New York,
NY (US); Alex V. Birk, Woodhaven, NY
(73) Assignee: Cornell Research Foundation, Inc.,
Ithaca, NY (US)
( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1215 days.
(21) Appl.No.: 10/838,135
(22) Filed: May 3, 2004
(65) Prior Publication Data
US 2005/0158373 Al Jul. 21, 2005
Related U.S. Application Data
(60) Provisional application No. 60/467,516, filed on May 1,2003.
Schiller, et al., "Opioid peptide analogs with novel activity profiles as potential therapeutic agents for use in analgesia", Peptide SciencePresent and Future, Proc. Int. Pept. Symp., 1st, Y. Shimonishi (ed), 1999, pp. 665-669.
Schiller, et al., "Opioid Peptide Analogs With Novel Activity Profiles as Potential Therapeutic Agents For Use in Analgesia", First International Peptide Symposium, Program & Abstracts, Nov. 30-Dec. 5, 1997, Kyoto, Japan, 0-36, p. 77.
Zhao, et al., "Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and ReperfUsion Injury", J. Biol. Chem., Aug. 2004, vol. 279, No. 33, pp. 34682-34690.
Clapp, et al., "Cardiovascular and metabolic responses to two receptor-selective opioid agonists in pregnant sheep", American Journal of Obstetrics and Gynecology, vol. 178, 1998, pp. 397-401. Din et al., "Studies on the Internalization Mechanism of Cationic Cell-penetrating Peptides", Journal of Biological Chemistry, 2003, 278:33, 31192-31201.
Richard et al., "Cell-penetrating Peptides", Journal of Biological Chemistry, 2003: 278:1, 585-590.
Schwarze, Steven R., et al., "In vivo Protein Transduction: Intracellular Delivery of Biologically Active Proteins, Compounds and DNA", Trends Pharmacol Sci. 2000, 21:45-48. Zhao, Kesheng, et al., "Translocation of a3+Net Charge Tetrapeptide Across Plasma Membrane of Mammalian Cells", Abstract published on-line May 1, 2002 for the World Congress of Pharmacology meeting held Jul. 7, 2002.
Zhao, Kesheng, et al., "Trancellular Transport of a Highly Polar 3+
Net Charge Opiod Tetrapepdide", Journal of Pharmacology and
Experimental Therapeutics 2003, 304(l):425-432.
Zhao, Guo-Min, et al., "Profound Spinal Tolerance after Repeated
Exposure to a Highly Selective |3-Opioid Peptide Agonist: Role of
8-Opioid Receptors," J. Pharma. Exper. Thera. 2002, 302(1) 188
Schiller et al., "Unsulfated C-Terminal 7-Peptide of Cholecystokinin: A New Ligand of the Opiate Receptor," Biochemical and Biophysical Research Communications, 85:1332-1338 (1978).
Holsey, et al. "Cardiovascular Effects of a u-Selective Opioid Agonist
(Tyrosine-D-Arginine-Phenylalanine-Lysine-NH2) in Fetal Sheep:
Sites and Mechanisms of Action", Am. J. Obstet. Gynecol., vol. 180,
No. 5 (May 1999) pp. 1127-1130.
Kett, et al. "Baroreflex-Mediated Bradycardia but Not Tachycardia is
Blunted Peripherally by Intravenous u-opioid Agonists", Am. J.
Obstet. Gynecol., vol. 178, No. 5 (May 1998) pp. 950-955.
Neilan, et al. "Pharmacological Characterization of the Dermorphin
Analog [Dmtl]DALDA, a Highly Potent and Selective u-Opioid
Peptide", European Journal of Pharmacology, vol. 419, Issue 1
Omoniyi, et al. "A Peripheral Site of Action for the Attenuation of
Baroreflex-Mediated Bradycardia by Intravenous u-Opioid
Agonists", Journal of Cardiovascular Pharmacology TM, vol. 3 5, No.
2 (2000) pp. 269-274.
Primary Examiner—Anish Gupta
(74) Attorney, Agent, or Firm—Foley & Lardner LLP
Schiller, et al. "Dermorphin Analogues Carrying an Increased Positive Net Charge in Their "Message" Domain Display Extremely High u-Opioid Receptor Selectivity", Journal of Medicinal Chemistry, vol. 32, No. 3 (1989) pp. 698-703.
Schiller, et al. "Synthesis and In Vitro Opioid Activity Profiles of DALDA Analogues", European Journal of Medicinal Chemistry, vol. 35, Issue 10 (Oct. 2000) pp. 895-901.
Shimoyama, et al. "Antinociceptive and Respiratory Effects of Intrathecal H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmtl] DALDA", The Journal of Pharmacology and Experimental Therapeutics, vol. 297, No. 1 (Apr. 2001) pp. 364-371. Szeto, etal. "In Vivo Disposition of Dermorphin Analog (DALDA) in Nonpregnant and Pregnant Sheep", The Journal of Pharmacology and Experimental Therapeutics, vol. 284, No. 1 (1998) pp. 61-65. Szeto, et al. "Respiratory Depression After Intravenous Administration of 8-Selective Opioid Peptide Analogs", Peptides, vol. 20 (1999) pp. 101-105.
Szeto, et al. "Mu-Opioid Receptor Densensitization and Resensitization In Vivo", International Narcotics Research Conference, Poster Abstracts, Monday (1999) Monl9, p. 5.
Szeto, etal. "In Vivo Pharmacokinetics of Selective u-Opioid Peptide Agonists", The Journal of Pharmacology and Experimental Therapeutics, vol. 298, No. 1 (Jul. 2001) pp. 57-61. Wu, et al. "Myocardial Protective Effect of Mu Opioid Agonists", International Narcotics Research Conference, Poster Abstracts, Sunday (1999) Sun59, p. 15.
Broekemeier, et al., "Inhibition of the Mitochondrial Permeability Transition by Cyclosporin A during Long Time Frame Experiments: Relationship between Pore Opening and the Activity of Mitochondrial Phospholipases", Biochemistry 1995, 34:1644016449.
Wu, et al., "A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning", Am J Physiol Heart Circ Physiol 2002, 283:H783-H791.
Fuhrman et al., "Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized lowdensity lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase", Atherosclerosis, Mar. 7, 2002, vol. 161, Iss 2, pp. 307-316, entire document. Herve, et al., "On the Immunogenic Properties of Retro-Inverso Peptides. Total Retro-Inversion of T-Cell Epitopes Causes a Loss of Binding to MHCII Molecules", Molecular Immunology, vol. 34, No. 2, pp. 157-163, 1997.
Guerrini, et al., "Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt] deltorphin B", European Journal of Pharmacology 302, (1996) 37-42. Abstract only.
File Medline on STN An No: 2005478947. Simmons, Zachary. "Management Strategies for Patients with Amyotrophic Lateral Sclerosis from Diagnosis Through Death". The Neurologist (Sep. 2005), vol. 11, No. 5, pp. 257-270. Abstract only.
Azzouz, Mimoun, "Gene Therapy For ALS: Progress and Prospects" Biochemical et Biophysica Acta (2006), vol. 1762 pp. 112-1127. Margolis, et al. "Diagnosis of Huntington Disease", Clinical Chemistry, vol. 49, No. 10 pp. 1726-1732 (2003).
Korczyn, et al. "Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease", Drugs vol. 62, No. 5, pp. 775-786. 2002.
Sriram, etal., "Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis", Ann. Neurol, vol. 58, pp. 939-945, 2005.
Steinman, et al., "How to Successfully Apply Animal Studies in
Experimental Allergic Encephalomyelitis to Research on Multiple
Sclerosis", Ann Neurol, vol. 60, pp. 12-21. 2006.
Citron, Martin, "Alzheimer's Disease: Treatments in Discovery and
Development", Nature Neuroscience Supplement, vol. 5 pp. 1055-
1057. Nov. 2002.
Patel, et al., "Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review", J. Geriatr. Psychiatry Neurol, vol. 8. pp. 81-95. 1995.
Zadina J. etal., "A Potent and Selective Endogeneous Agonist for the Mu-Opiate Receptor", Nature, Nature Publishing Group, London, GB, vol. 386, Apr. 3, 1997, pp. 499-502, XP002072008.
Spetea, Mariana et al., "Interaction of agonist peptide (3H) Tyr-DAla-Phe-Phe-NH2 with mu-opioid receptor in rat brain and CHOmu/1 cell line", Peptides (New York), vol. 19, No. 6, 1998, pp. 1091-1098, XP002410285.
Dooley, C T et al., "Selective ligands for the mu, delta and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library", Journal of Biological Chemistry, American Society of Biochemistry and Molecular Biology, Birmingham, US, vol. 273, No. 30, Jul. 24, 1998, pp. 1884818856 XP002100725.
Schiller, PW. et al., "Opioid peptide analogs with novel activity profiles as potential therapeutic agents for use in analgesia", STN CAPLUS, No. 132:102403, 1997, XP002933635. Bork, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", 2000, Genome Research 10:398-400.
Skolnick et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", 2000, Trends in Biotech. 18(l):34-39.
Doerks et al., "Protein annotation: detective work for function prediction", 1998, Trends in Genetics 14:248-250. Smith et al., "The challenges of genome sequence annotation or 'The devil is in the details'", 1997, Nature Biotechnology 15: 1222-1223. Brenner, "Errors in genome annotation", 1999, Trends in Genetics 15:132-133.
Bork et al., "Go hunting in sequence databases but watch out for the traps", 1996, Trends in Genetics 12:425-427. James A Wells, "Additivity of Mutational Effects in Proteins", Biochemistry, American Chemical Society, vol. 29, No. 37, Sep. 18, 1990.
Lishmanov et al., "Ligands for Opioid and 8-Receptors Improve Cardiac Electrical Stability in Rat Models of Post-Infarction Cardiosclerosis and Stress", Life Sciences. 1999; 65: PL 13-17. DEMAS et al., "Anaesthesia for Heart Transplantation", Br J Anaesth. 1986; 58: 1357-1564.
Shroff et al., "Effects of Intrathecal Opioid on Extubation Time, Analgesia, and Intensive Care Unit Stay Following Coronary Artery Bypass Grafting", Journal of Clinical Anesthesia. 1997;9: 415-419. Lasukova et al., "Activation of mu-opioid receptors and cardiomyocyte resistance to free radical damage", Patol Fiziol Eksp Ter. 2001 2: Abstract Only; article in Russian. Song et al., "A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats", Coronary Artery Disease, 2005: 16: 407-410.
Rudinger, J. (1976), Peptide Hormones (Ed. J. A. Parson), University Park Press, Baltimore, pp. 1-7.
Bradley et al., "Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat", J. Mol. Biol. vol. 324, pp. 373-386. 2002.
Berendsen, Herman, "A Glimpse of the Holy Grail?", Science, vol. 282, pp. 642-643, Oct. 23, 1998.
Ngo, et al., "Computational Complexity, Protein Structure Prediction, and the Levinfhal Paradox", The Protein Folding Problem and Tertiary Structure Prediction, K. Merz, Jr. and S. Le Grand, Editors, Birkhauser Boston, 1994.
Pages et al., "Cystamine and Cysteamine Increase Brain Levels of BDNF in Huntington Disease Via HSJlb and Transglutaminase", JournalofClinicalInvestigation, vol. 116No. 5,pp. 1410-1424.May 2006.
Dimaio, et al., "Synthesis and Pharmacological Characterization in Vitro of Cyclic Enkephalin Analogues: Effect of Conformational Constraints on Opiate Receptor Selectivity", J. Med. Chem. 25:14321438 (1982).
Majer et al., "Synthesis of Methylated Phenylalanines Via Hydrogenolysis of Corresponding 1, 2, 3, 4 Tetrahydroisoquinoline3-Caraboxylic Acids,", Int. Journal of Peptide & Protein Research, 43:62-68 (1994).
Schiller et al., "Tipp: A Highly Potent and Stable Pseudopeptide 8 Opioid Receptor Antagonist with Extraordinary 8 Selectivity", J. Med. Chem. 36:3182-3187 (1993).
* cited by examiner
< *" <- ° ° U
<>j (ujaiOJd BLU/|oaid) 8>|eidn ... (u!3»ojd Bw/iowd) 3>)e}dn ...